Search results
Showing 91 to 105 of 2084 results for technology appraisal
Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.
Awaiting development Reference number: GID-TA11437 Expected publication date: TBC
Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
experience an acute pulmonary embolism or deep vein thrombosis. As in NICE technology appraisal guidance 261 it is recommended that...
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab (Gazyvaro) for untreated chronic lymphocytic leukaemia in adults.
Show all sections
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (TA1102)
NICE is unable to make a recommendation on iptacopan (Fabhalta) for treating complement 3 glomerulopathy in adults. This is because the company has withdrawn from the appraisal.
Show all sections
Sections for TA1102
Evidence-based recommendations on using coronary artery stents in adults.
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
NICE Funding Variation Request Consultation: methods / process manual consultation
We are listening to your views on this NICE process and methods. Comments close 19 June 2026.
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.